Complete financial analysis of Takeda Pharmaceutical Company Limited (TAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Takeda Pharmaceutical Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Mipco Seamless Rings (Gujarat) Limited (MPCOSEMB.BO) Income Statement Analysis – Financial Results
- Hess Corporation (HES) Income Statement Analysis – Financial Results
- Kensington Capital Acquisition Corp. V (KCGI-UN) Income Statement Analysis – Financial Results
- Lavipharm S.A. (LAVI.AT) Income Statement Analysis – Financial Results
- PT Toba Pulp Lestari Tbk (INRU.JK) Income Statement Analysis – Financial Results
Takeda Pharmaceutical Company Limited (TAK)
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,263.76B | 4,027.48B | 3,569.01B | 3,197.81B | 3,291.19B | 2,097.22B | 1,770.53B | 1,732.05B | 1,807.38B | 1,777.82B | 1,691.69B | 1,557.27B | 1,508.93B | 1,419.39B | 1,465.97B | 1,538.34B | 1,374.80B | 1,305.17B | 1,212.21B | 1,122.96B | 1,086.43B | 1,046.08B | 1,005.06B | 963.48B | 923.13B |
| Cost of Revenue | 1,431.51B | 1,244.07B | 1,106.85B | 994.31B | 1,089.76B | 659.69B | 495.92B | 558.76B | 535.41B | 520.99B | 490.26B | 447.63B | 433.19B | 317.58B | 285.06B | 289.54B | 278.63B | 279.66B | 282.10B | 279.18B | 269.40B | 300.34B | 337.85B | 384.01B | 432.33B |
| Gross Profit | 2,832.26B | 2,783.41B | 2,462.16B | 2,203.50B | 2,201.42B | 1,437.53B | 1,274.61B | 1,173.30B | 1,271.97B | 1,256.83B | 1,201.42B | 1,109.64B | 1,075.74B | 1,101.80B | 1,180.90B | 1,248.79B | 1,096.17B | 1,025.51B | 930.11B | 843.78B | 817.04B | 745.74B | 667.21B | 579.47B | 490.80B |
| Gross Profit Ratio | 66.43% | 69.11% | 68.99% | 68.91% | 66.89% | 68.54% | 71.99% | 67.74% | 70.38% | 70.70% | 71.02% | 71.26% | 71.29% | 77.63% | 80.55% | 81.18% | 79.73% | 78.57% | 76.73% | 75.14% | 75.20% | 71.29% | 66.38% | 60.14% | 53.17% |
| Research & Development | 729.92B | 633.33B | 526.09B | 455.83B | 492.38B | 368.30B | 325.44B | 312.30B | 345.93B | 382.10B | 341.56B | 324.29B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 499.40B | 450.96B | 811.62B | 810.71B | 640.20B | 666.68B | 834.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 385.96B | 0.00 | 319.36B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.21B | 105.25B | 175.52B | 0.00 | 94.52B | 94.01B | 108.10B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1,053.82B | 997.31B | 886.36B | 875.66B | 964.74B | 717.60B | 628.11B | 619.06B | 650.77B | 612.61B | 556.21B | 987.13B | 810.71B | 734.72B | 760.69B | 942.33B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 385.96B | 0.00 | 319.36B |
| Other Expenses | 834.44B | 662.27B | 588.87B | 362.74B | 643.90B | 908.87B | 707.38B | 705.13B | 795.22B | 1,003.99B | 720.59B | 5.81B | 0.00 | 3.78B | 735.00M | 12.13B | 673.05B | 567.01B | 527.30B | 458.50B | 445.40B | 435.05B | 0.00 | 353.37B | 0.00 |
| Operating Expenses | 2,618.18B | 2,292.90B | 2,001.32B | 1,694.24B | 2,101.02B | 1,277.17B | 1,032.82B | 1,017.43B | 1,141.15B | 1,386.09B | 1,062.15B | 987.13B | 810.71B | 734.72B | 760.69B | 942.33B | 673.05B | 567.01B | 527.30B | 458.50B | 445.40B | 435.05B | 385.96B | 353.37B | 319.36B |
| Cost & Expenses | 4,049.69B | 3,536.97B | 3,108.16B | 2,688.54B | 3,190.78B | 1,936.86B | 1,528.74B | 1,576.18B | 1,676.55B | 1,907.08B | 1,552.41B | 1,434.76B | 1,243.91B | 1,052.30B | 1,045.75B | 1,231.87B | 951.68B | 846.67B | 809.40B | 737.68B | 714.80B | 735.40B | 723.82B | 737.38B | 751.69B |
| Interest Income | 11.29B | 62.91B | 23.70B | 105.52B | 27.83B | 6.62B | 39.54B | 12.27B | 21.65B | 15.36B | 49.30B | 16.30B | 6.30B | 1.73B | 1.98B | 11.38B | 62.06B | 56.24B | 34.21B | 18.10B | 10.90B | 10.13B | 9.61B | 9.93B | 0.00 |
| Interest Expense | 119.54B | 169.70B | 166.61B | 248.63B | 165.01B | 48.16B | 31.93B | 23.25B | 31.93B | 32.88B | 30.72B | 3.32B | 1.88B | 1.34B | 1.43B | 1.62B | 333.00M | 247.00M | 365.00M | 334.00M | 359.00M | 420.00M | 759.00M | 1.02B | 1.19B |
| Depreciation & Amortization | 728.00B | 664.40B | 583.15B | 559.67B | 583.65B | 247.69B | 182.13B | 171.43B | 181.24B | 260.95B | 215.74B | 201.11B | 150.19B | 106.72B | 114.83B | 118.08B | 31.69B | 28.82B | 28.73B | 31.23B | 28.08B | 29.96B | 28.43B | 33.61B | 33.36B |
| EBITDA | 900.33B | 1,156.46B | 1,183.21B | 983.72B | 880.33B | 464.22B | 359.96B | 296.88B | 349.85B | 148.39B | 368.18B | 351.18B | 421.82B | 479.63B | 537.64B | 518.25B | 608.87B | 654.45B | 547.05B | 472.66B | 474.59B | 462.28B | 402.62B | 297.70B | 237.32B |
| EBITDA Ratio | 21.12% | 30.02% | 29.49% | 36.73% | 20.90% | 17.95% | 24.36% | 22.48% | 19.36% | 8.35% | 23.96% | 22.55% | 27.95% | 34.12% | 36.67% | 28.78% | 44.53% | 48.03% | 43.89% | 42.75% | 44.48% | 42.00% | 38.20% | 30.16% | 27.31% |
| Operating Income | 214.08B | 490.51B | 460.84B | 509.27B | 100.41B | 204.97B | 241.79B | 155.87B | 130.83B | -129.25B | 139.27B | 122.51B | 265.03B | 367.08B | 420.21B | 306.47B | 423.12B | 458.50B | 402.81B | 385.28B | 371.63B | 310.69B | 281.24B | 226.10B | 171.44B |
| Operating Income Ratio | 5.02% | 12.18% | 12.91% | 15.93% | 3.05% | 9.77% | 13.66% | 9.00% | 7.24% | -7.27% | 8.23% | 7.87% | 17.56% | 25.86% | 28.66% | 19.92% | 30.78% | 35.13% | 33.23% | 34.31% | 34.21% | 29.70% | 27.98% | 23.47% | 18.57% |
| Total Other Income/Expenses | -161.28B | -115.42B | -158.27B | -143.03B | -161.16B | -77.36B | -24.58B | -12.52B | -10.29B | -16.18B | -1.60B | 10.56B | -12.55B | 4.49B | -4.38B | 92.08B | 153.72B | 166.88B | 115.15B | 55.82B | 74.51B | 121.21B | 92.18B | 36.97B | 31.32B |
| Income Before Tax | 52.79B | 375.09B | 302.57B | 366.24B | -60.75B | 94.90B | 217.21B | 143.35B | 120.54B | -145.44B | 158.85B | 129.71B | 252.48B | 371.57B | 415.83B | 398.55B | 576.84B | 625.38B | 517.96B | 441.10B | 446.14B | 431.90B | 373.43B | 263.08B | 202.76B |
| Income Before Tax Ratio | 1.24% | 9.31% | 8.48% | 11.45% | -1.85% | 4.52% | 12.27% | 8.28% | 6.67% | -8.18% | 9.39% | 8.33% | 16.73% | 26.18% | 28.37% | 25.91% | 41.96% | 47.92% | 42.73% | 39.28% | 41.07% | 41.29% | 37.15% | 27.30% | 21.96% |
| Income Tax Expense | -91.41B | 58.05B | 72.41B | -9.94B | -105.04B | -14.12B | 30.50B | 27.83B | 37.06B | -2.40B | 49.29B | -3.88B | 125.21B | 121.33B | 115.67B | 161.35B | 218.77B | 285.84B | 201.36B | 160.23B | 157.91B | 157.49B | 134.89B | 114.15B | 81.45B |
| Net Income | 144.07B | 317.02B | 230.06B | 376.01B | 44.24B | 109.13B | 186.89B | 114.94B | 80.17B | -145.78B | 106.66B | 131.24B | 124.16B | 247.87B | 297.74B | 234.39B | 355.45B | 335.81B | 313.25B | 277.44B | 285.26B | 271.76B | 235.66B | 146.86B | 119.63B |
| Net Income Ratio | 3.38% | 7.87% | 6.45% | 11.76% | 1.34% | 5.20% | 10.56% | 6.64% | 4.44% | -8.20% | 6.30% | 8.43% | 8.23% | 17.46% | 20.31% | 15.24% | 25.85% | 25.73% | 25.84% | 24.71% | 26.26% | 25.98% | 23.45% | 15.24% | 12.96% |
| EPS | 91.16 | 204.29 | 147.14 | 240.72 | 28.41 | 56.75 | 119.67 | 73.58 | 51.13 | -92.69 | 67.55 | 94.11 | 78.65 | 157.01 | 188.60 | 144.91 | 209.49 | 193.00 | 176.74 | 156.51 | 160.93 | 153.82 | 133.51 | 83.20 | 67.78 |
| EPS Diluted | 91.16 | 201.94 | 145.87 | 238.96 | 28.25 | 56.43 | 118.78 | 73.13 | 50.86 | -92.69 | 67.47 | 94.09 | 78.63 | 156.98 | 188.57 | 144.90 | 209.49 | 193.00 | 176.74 | 156.51 | 160.93 | 153.82 | 133.51 | 83.20 | 67.78 |
| Weighted Avg Shares Out | 1.58B | 1.55B | 1.56B | 1.56B | 1.56B | 1.92B | 1.56B | 1.56B | 1.57B | 1.57B | 1.58B | 1.58B | 1.58B | 1.58B | 1.58B | 1.62B | 1.70B | 1.74B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
| Weighted Avg Shares Out (Dil) | 1.58B | 1.57B | 1.58B | 1.57B | 1.57B | 1.93B | 1.57B | 1.57B | 1.58B | 1.57B | 1.58B | 1.58B | 1.58B | 1.58B | 1.58B | 1.62B | 1.70B | 1.74B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
On Tuesday, Takeda Pharmaceutical Company Limited TAK entered into an exclusive licensing agreement with Keros Therapeutics, Inc. KROS to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau....
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
TOKYO & BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda's proprietary...
Hennessy Japan Fund's Masa Takeda on the top Japanese stocks investors should watch
Masa Takeda, portfolio manager at Hennessy Japan Fund, joins CNBC's 'Power Lunch' to discuss why he's bullish on Japan, what president-elect Trump's proposed tariffs could mean for Japanese companies, and more.
Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2025 Earnings Call October 31, 2024 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump...
Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments
Japan's Takeda Pharmaceutical returned to profitability in the second quarter following large impairment losses a year earlier and is restructuring to cut costs.
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year...
Takeda Pharmaceuticals: An Interesting Option For Income Investors
Takeda Pharmaceuticals (NYSE: TAK) offers a strong cash position and above-average dividend yield, making it an attractive option for income investors seeking international pharma exposure. The company's price/book value of 0.92 suggests it may be undervalued, presenting a potential long-term...
TAK or CTLT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Source: https://incomestatements.info
Category: Stock Reports